Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD418 in HFrEF
NCT05139615Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of APD418 in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Pfizer. Primary endpoint: Change in Cardiac Index at 6 hours. Started Dec 2021; status: terminated.
02
Drugs
APD418
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05139615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139615.